疏肝健脾方含药血清对酒精性损伤HepG2细胞脂肪变性的保护作用

doi:10.3969/j.issn.1672-5069.2016.02.009

摘要/Abstract

摘要： 目的探讨疏肝健脾方含药血清对酒精性损伤HepG2细胞脂肪变性的保护作用。方法采用酒精诱导HepG2细胞损伤模型,设立正常对照组、模型组、含药血清组（疏肝健脾方含药血清）和正常血清组,观察HepG2细胞形态以及生长情况;采用MTT法检测细胞活力,采用油红O染色对存活HepG2细胞脂肪变程度进行观察和量化比较,采用免疫印迹法检测HepG2细胞过氧化物酶体增殖物激活受体（PPAR）γ蛋白表达水平。结果含药血清组细胞形态与正常对照组HepG2细胞形态相似,细胞形态完整,贴壁生长状态良好;含药血清组和正常对照组HepG2细胞脂肪变程度十分接近,脂肪变程度较轻;油红O染色显示,异丙醇溶液脱色后吸光度测定值在模型组为（0.942±0.051）,正常血清组为（0.928±0.049）,均显著高于含药血清组（0.619±0.043）和正常对照组【（0.621±0.050,P<0.05】;MTT吸光度值在正常对照组为（1.021±0.071）,在含药血清组为（0.962±0.066）,也显著高于模型组（0.561±0.035）和正常血清组【（0.572±0.041）,P<0.05】;正常对照组和含药血清组HepG2细胞PPARγ蛋白表达水平显著低于模型组和正常血清组（P<0.05）。结论疏肝健脾方含药血清对酒精性损伤HepG2细胞脂肪变性有保护作用。

关键词: 酒精性脂肪肝, HepG2细胞, 疏肝健脾方, 脂肪代谢

Abstract: Objective To explore the effect of Shuganjianpi decoction in the prevention of alcohol-induced steatosis in HepG2 cells in vitro. Methods Cellular injury of HepG2 cells were induced by alcohol treatment, and HepG2 cells were divided into four groups, e.g. control group (group A）, alcohol-treated group (group B）, serum containing Shuganjianpi decoction treated group (group C） and normal serum treated group (group D）. Cellular morphology and growth were observed. Cell viability was tested by MTT assay. The degree of steatosis in viable cells was evaluated by Oil red O staining, and the expression of peroxisome proliferator-activated receptor-γ(PPAR-γ） was detected by Western blotting assay. ResultsThe cells in group A and group C had similar morphological manifestations and good performance of adherence, and similar mild extent of steatosis; Oil red O staining revealed that after the decolorization by isopropyl alcohol solution, absorbance value in group B (0.942 ± 0.051） and group D (0.928±0.049） were significantly higher than those in group C (0.619±0.043） or in group A [(0.621±0.050）, P<0.05]; MTT assay showed that the absorbance value in group A(1.021±0.071） and group C (0.962±0.066） were significantly higher than in group B (0.561 ± 0.035） and group D [(0.572±0.041）, P<0.05]; The expression of PPARγ protein decreased in group A and group C than in group B and group D did (P<0.05）. Conclusions The effect of Shuganjianpi decoction is effective in the prevention of alcohol-induced steatosis in HepG2 cells.

Key words: Alcoholic fatty liver, HepG2 cell, Shuganjianpi decoction, Lipid metabolism

郭灿, 曾莉. 疏肝健脾方含药血清对酒精性损伤HepG2细胞脂肪变性的保护作用[J]. 实用肝脏病杂志, 2016, 19(2): 160-163.

Guo Can, Zeng Li. Effect of Shuganjianpi decoction in the prevention of alcohol-induced steatosis in HepG2 cells[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 160-163.

参考文献

[1] Tipoe GL, Liong EC, Casey CA, et al. A voluntary oral ethanol-feeding rat model associated with necroinflammatory liver injury. Alcohol Clin Exp Res,2008,24(32）:669-682.
[2] 何东,王晓雨,程玉刚,等.D-木糖对酒精致肝细胞脂肪性变的保护作用.世界华人消化杂志,2012,20(24）:2259-2264.
[3] Wang HJ, Zakhari S, Jung MK. Alcohol, inflammation, and gut-liver-brain interactions in tissue damage and disease development.World J Gastroenterol, 2010, 35(16）:1304-1313.
[4] 韩海啸,江一墩,王志斌,等.当归白术汤加减治疗新马地区酒精性脂肪肝的临床研究.中华中医药学刊,2011,30(2）:435-437.
[5] 徐开武.酒精性脂肪肝中西医治疗效果分析.时珍国医国药,201,22(12）:3075-3076.
[6] 何培元,高淑梅,侯志平,等.白藜芦醇对酒精诱导的HepG2细胞氧化损伤的保护作用及相关基因表达的变化.世界华人消化杂志,2014,22(14）:1928-1935.
[7] 何培元,高淑梅,张聪,等.白藜芦醇通过MEK/ERK-SIRT1通路的激活调节酒精诱导的HepG2细胞凋亡损伤.世界华人消化杂志,2014,22(21）:3011-3018.
8] 万雪梅,欧阳海平,唐诗韵,等.中药治疗酒精性脂肪肝临床研究文献的系统评价.四川医学,2015,36(3）:343-347.
[9] Holownia AR, Mroz M, Wielgat P, et al. Histone acetylation and arachidonic acid cytotoxicity in HepG2 cells overexpressing CYP2E1. Naunyn Schmiedebergs Arch Pharmacol, 2014, 387(3）: 271-280.
[10] 李全征,赵远红,李正,等.探讨益肝降脂方对大鼠酒精性脂肪肝病理影响与疗效的相关性.天津中医药,2015,32(2）:93-97.
[11] Shen ZX, Liu C, Liu PP, et al. Sphingosine 1-phosphate (S1P） promotes mitochondrial biogenesis in Hep G2 cells by activating peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α）. Cell Stress Chaperones, 2014, 19(4）: 541-548.
[12] Singh CK, Kumar A, Lavoie HA, et al. Diabetic complications in pregnancy: is resveratrol a solution. Exp Biol Med (Maywood） ,2013, 238(3）:482-490.
[13] Lee JH, Banerjee A, Ueno Y, et al. Potential relationship between hepatobiliary osteopontin and peroxisome proliferator-activated receptor α expression following ethanol-associated hepatic injury in vivo and in vitro. Toxicol Sci, 2008, 106(1）:290-299.
[14] 李秀丽,章琳,李影娜,等.PPARγ-2基因Pro12Ala多态性与2型糖尿病及其一级亲属血脂的相关性研究.西安交通大学学报(医学版）,2013,77(5）:632-636.
[15] 屈耀宁,董蕾,史海涛,等. 己酮可可碱对小鼠酒精性肝病酒精代谢酶和核受体PPAR-α 的影响.实用肝脏病杂志,2014,17（2）：163-167.
16] 李培,杨亚兵,刘梅林.血脂康对脂肪肝大鼠过氧化物酶体增殖物活化受体γ及小凹蛋白1的影响.中华老年心脑血管病杂志,2012,13(1）:76-79.
[17] 张元琛,田强,党毓起,等.回药复方软化动脉胶囊对糖尿病并发动脉粥样硬化大鼠血糖及主动脉PPAR-γ基因表达的影响.宁夏医科大学学报,2015,37(1）:1-3,13.
[18] 刘淑敏,孙超,谢伟华.决明子提取物对高血脂模型小鼠聚脂基因表达的影响.中草药,2009,30(4）:583-587.
[19] 邹正升,李保森,黄昂,等. 近10年4种常见的非感染性肝病患者临床特征及变化趋势分析.实用肝脏病杂志,2014,17（5）：475-478.
[20] 王峥嵘,马国平,王敬,等.红景天提取物对代谢综合征大鼠肝脏PPAR-αmRNA、PPAR-γmRNA表达的影响.河北中医药学报,2014,29(1）:42-43,54.

[1]	张莹, 王洪岩, 迟程, 徐有青. LPS诱导的HepG2细胞NOTCH与LPS-TLR4-NF-κB炎症信号通路的“会话”研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 470-473.
[2]	王爽, 许坚吉, 刘晓霓, 陈德喜. 荧光素酶生物发光报告体系的优化及在肝癌荷瘤裸鼠模型中的应用^*[J]. 实用肝脏病杂志, 2019, 22(4): 482-485.
[3]	曹白鸽,刘冲霄,陈源文,董艳. IL-6上调SCD1表达对HepG2细胞脂质合成功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(2): 172-175.
[4]	张小三, 张一鸣, 杨树军, 戚春辉, 刘凯, 赵燕. miR-21对HepG2细胞增殖、凋亡和细胞周期的影响^*[J]. 实用肝脏病杂志, 2019, 22(1): 21-24.
[5]	姜哲, 舒敏, 王媛媛, 朴莲淑. miR-363靶向调控E2F3表达影响HepG2细胞增殖和凋亡研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 825-828.
[6]	黄娇凤, 林苏, 王明芳, 黄映芳, 熊美连, 朱月永. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效及其对肝组织脂肪变的影响^*[J]. 实用肝脏病杂志, 2018, 21(6): 863-867.
[7]	浦永兰, 陈源文, 范建高. 麦胶性肠病并发非酒精性脂肪肝1例报告[J]. 实用肝脏病杂志, 2018, 21(6): 981-982.
[8]	欧志涛, 詹远京, 郭家伟, 罗铎. CIAPIN1对HepG2细胞增殖和细胞周期的影响[J]. 实用肝脏病杂志, 2018, 21(1): 38-41.
[9]	陆检英，郑国银，彭浩，李欢，周海燕，张高彬. 甘枣宁颗粒治疗非酒精性脂肪肝临床疗效及安全性分析[J]. 实用肝脏病杂志, 2017, 20(6): 709-712.
[10]	李笠, 梁学亚. 水飞蓟宾葡甲胺联合多烯磷脂酰胆碱治疗酒精性脂肪肝患者初步临床研究[J]. 实用肝脏病杂志, 2017, 20(4): 412-415.
[11]	王以浪，印滇，杨莉，张亮，姚登福. 胰岛素抵抗肝癌细胞IGF-1R/NF-κB表达及多药耐药机制研究[J]. 实用肝脏病杂志, 2016, 19(6): 704-708.
[12]	丁宁, 张明香. 人HNF4α基因真核表达载体的构建与鉴定^*[J]. 实用肝脏病杂志, 2016, 19(2): 156-159.
[13]	阎劲松, 袁丹, 李东升. 影响2型糖尿病患者新发非酒精性脂肪肝相关因素分析^*[J]. 实用肝脏病杂志, 2016, 19(2): 212-213.
[14]	王菲, 王炳元. 酒精性肝病的少见表现：马德龙综合征[J]. 实用肝脏病杂志, 2014, 17(3): 287-291.
[15]	冯凯瑜. 复方牛胎肝提取物治疗非酒精性脂肪肝临床观察[J]. 实用肝脏病杂志, 2014, 17(3): 311-313.